

# SECURITIES AND EXCHANGE COMMISSION

## FORM CERT

Filing Date: **2022-05-16**  
SEC Accession No. [0001354457-22-000302](#)

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### **Bellevue Life Sciences Acquisition Corp.**

CIK: [1840425](#) | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
Type: **CERT** | Act: **34** | File No.: [001-41390](#) | Film No.: **22928196**  
SIC: **6770** Blank checks

Mailing Address  
*10900 NE 4TH STREET,  
SUITE 2300  
BELLEVUE WA 98004*

Business Address  
*10900 NE 4TH STREET,  
SUITE 2300  
BELLEVUE WA 98004  
425-635-7700*

**Eun Ah Choi**  
Senior Vice President  
U.S. Listing Qualifications & Market Surveillance

May 16, 2022

Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on May 11, 2022, The Nasdaq Stock Market LLC (the "Exchange") received from Bellevue Life Sciences Acquisition Corp. the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Units, each consisting of one share of common stock and one redeemable warrant

Common stock, par value \$0.0001

Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

